Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 93.63M P/E - EPS this Y 96.70% Ern Qtrly Grth -
Income -22.93M Forward P/E -1.70 EPS next Y -5,000.00% 50D Avg Chg -10.00%
Sales 63.91M PEG -1.15 EPS past 5Y - 200D Avg Chg -4.00%
Dividend N/A Price/Book 3.49 EPS next 5Y 61.20% 52W High Chg -50.00%
Recommedations 1.60 Quick Ratio 0.77 Shares Outstanding 4.56M 52W Low Chg 126.00%
Insider Own 7.34% ROA -26.72% Shares Float 3.88M Beta 1.11
Inst Own 29.29% ROE - Shares Shorted/Prior 83.71K/9.77K Price 1.04
Gross Margin -9.62% Profit Margin -35.88% Avg. Volume 876,140 Target Price 81.25
Oper. Margin -34.55% Earnings Date Aug 1 Volume 710,387 Change 0.00%
About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics, Inc. News
05/15/24 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
05/15/24 Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
04/26/24 Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
04/25/24 Cidara buys back rights to flu therapy from J&J for $85m
04/24/24 Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
04/24/24 Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
04/22/24 Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
04/22/24 Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
04/22/24 Cidara Therapeutics Announces Reverse Stock Split
04/05/24 Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/06/24 Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
02/15/24 Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
02/12/24 Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
01/29/24 Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
12/26/23 Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
12/22/23 Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
12/07/23 Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
12/06/23 Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
11/30/23 Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
11/20/23 Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
CDTX Chatroom

User Image Maxim89 Posted - 7 hours ago

$CDTX For those who missed the info: https://fox2now.com/business/press-releases/globenewswire/9118408/cidara-therapeutics-regains-compliance-with-nasdaq-continued-listing-rules/

User Image BrightHope Posted - 22 hours ago

$CDTX can buy under $1 again. Wait for few months.

User Image Tauro83 Posted - 1 day ago

$CDTX Have there been a PR about the removal of the non compliant list or did I miss it?

User Image TangoToEvora Posted - 1 day ago

$CDTX This is me with Cidara shares now :)

User Image Shawhwk Posted - 1 day ago

$CDTX Where is CaliEpress and her opinion?

User Image Shawhwk Posted - 1 day ago

$CDTX There is absolutely no reason to beat this stock up after hours. At this rate we will be at $5.00 in a month. I seriously just don't get it. Why won't they let this stock trade at its market value.

User Image Maxim89 Posted - 1 day ago

$CDTX It's time for CDTX to make a +200%! $CMRX $KRON $EBS $MRKR

User Image Gbaltazar Posted - 1 day ago

$CDTX cutting my loss here 😪 100k to the trash ... 🗑 worst decision and Investment in my life . 😭

User Image Shawhwk Posted - 1 day ago

$CDTX Are people buying or selling. The valuation of this stock is well above $20.00. Investors may just be tired of this roller coaster and selling, taking the loss. Some money is better than no money.

User Image 4real2 Posted - 1 day ago

$CDTX what a sh*t show,down 8% on 52k volume only. Iam down 54% and the bottom is not even near.

User Image Unterhund70 Posted - 1 day ago

$CDTX the company's updated corporate presentation shows the CBO421 IND in late Q2 (so very soon) and Phase 1 Study starting in Q3. My understanding is that the PIPE will be funding CD388 Phase 2b only, so additional funds will be needed to continue CBO421 development. However, as the company isn't eligible to "register the offer and sale of securities using a registration statement on form S-3" until next year, doesn't that pretty much force a partnership on CBO421 to support development, and soon (June)? Very long and very patient...

User Image _nic Posted - 1 day ago

$CDTX time to avg down. I think q2 er should be interesting. Valuation of cd388, cash on hand, converted shares. But untill then - 🦗

User Image gazza01 Posted - 1 day ago

$CDTX out for the time being (at least 2 months)

User Image Shawhwk Posted - 1 day ago

$CDTX By the end of this year we will need another RS just to stay listed.

User Image kampochea Posted - 1 day ago

$CDTX 05/16/2024 Needham =>Joseph Stringer : → $25 Reiterates Buy → Buy

User Image dl42 Posted - 2 days ago

$CDTX might need to speed it up

User Image rickahuna Posted - 2 days ago

$CDTX If and when the CD388 and CBO421 are in phase 3 studies, this stock will be astronomical. But, I've been in this stock for 5 years and it has been a total disappointment. Every time, it rises and you expect it to go to the moon, Stein and company screw something up. The Cloudbreak platform is amazing, the researchers are amazing, but the management is atrocious. I understand the new direction to concentrate on Influenza and Cancer, because these pipelines are where the big money is down the road. However, they paved over the smaller investors (even though some of us have more than management) to make this new path.

User Image Nebler Posted - 2 days ago

$CDTX bagholder universe here. Thanks Jeff - for nothing

User Image _nic Posted - 2 days ago

$CDTX halted?

User Image Texout Posted - 2 days ago

$CDTX someone taking the block on offer realising it is still cheaper than the raise at 14,2… Nothing about yesterday’s result is a surprise just that it actually came just in time to not mess up compliance. With this tiny free float anything can happen

User Image Unterhund70 Posted - 2 days ago

@open_outcry @Thestocktraderhubzee $CDTX given the impact of the PIPE, per p.62 of the updated corporate presentation, that $25 price target implies a fully diluted market cap of about $578M, vs. their previous $3 target (market cap of $373M implied fully dilluted pre PIPE and split). The difference between these is actually a small premium over the impact of the added net cash from the PIPE. So basically, they are bullish and have firmed up their target. My two cents and sloppy math... Any way you cut it, the risk-reward still looks great to me at current prices.

User Image open_outcry Posted - 2 days ago

$CDTX anyone have access to options trading for this ticker via their brokerage? i'm on RH and still no options

User Image Thestocktraderhubzee Posted - 2 days ago

$CDTX Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target

User Image TangoToEvora Posted - 2 days ago

$CDTX

User Image TaylorTX Posted - 2 days ago

$CDTX patience is key here.

User Image open_outcry Posted - 3 days ago

$CDTX should grant its longest-standing, most-underwater shareholders naming rights for cd388 once it is approved. as one of those shareholders, and in memory of rezzayo, i propose NOFLUYO

User Image Gbaltazar Posted - 3 days ago

$CDTX I can't stand this management !! Can't put their shit together on time . No remorse or sympathy for investors .. I thought they had something going on under their sleeve but now I don't know what to expect from the incompetent people running company.. I invested on great potential company but never thought people behind it were such mediocres ..

User Image Joesh82 Posted - 3 days ago

$CDTX I was wondering about this as I have shares in another company with a similar issue, the company can't sell ATM shares or do offerings due to a late filing. I guess in Cidara's case they have the $155m to rely on but it looks like we are safe from dilution for a while. "As of March 31, 2024, the remaining capacity under the Sales Agreement was $37.1 million....We will not be able to sell shares of our common stock under the Sales Agreement until April 16, 2025, due to the loss of our Form S-3 eligibility" "As a result of our failure to timely file our Annual Report on Form 10-K for the year ended December 31, 2023, we lost our Form S-3 eligibility for primary and secondary offerings for at least 12 months following the date our Annual Report on Form 10-K filing was first delinquent, or through April 16, 2025."

User Image Shawhwk Posted - 3 days ago

$CDTX 2nd quarter will be even worse. Zero revenue and all cash burn with no trials on CD388 until flu season. Going to be a rough few quarters.

User Image RealAvidTrader Posted - 3 days ago

$CDTX $CDTX Sorry For Posting 3x 💥PLEASE READ THIS💥 Per The Recent Earnings Cidara Had: $29M Cash Add: + $240M (PIPE) = $269M 👉$58 Net Cash Per Share👈 Subtract: $85M For CD388 = $184M Divide: 4.5 (OS) = $41 Cash Per Share Now Lets Do Some Thinking: They’re Burning Roughly -$5M Per Quarter, Lets Call it -$10M To Be Super Fair. Next 3 Quarters They Burn -$30M Total Which Takes Us To $154M Or: $34 Cash Per Share. Call it $30 Thats Almost THREE TIMES THE CURRENT SHARE PRICE IN CASH BY END OF YEAR!! $41 Currently (3.5X share price) During the three months ended March 31, 2024, Cidara did not sell shares of common stock pursuant to its at-the-market sales agreement. As of March 31, 2024, Cidara had 4,561,696 shares of common stock outstanding and 2,104,472 shares of Series X Convertible Preferred Stock outstanding, which are convertible into 1,052,236 shares of common stock. Divide 1,052,236 / 4,561,696 = 0.23066772 (23%)

Analyst Ratings
Needham Buy May 16, 24
WBB Securities Strong Buy Apr 25, 24
Needham Buy Apr 25, 24
Cantor Fitzgerald Overweight Apr 25, 24
Cantor Fitzgerald Overweight Apr 23, 24
HC Wainwright & Co. Buy Apr 8, 24
HC Wainwright & Co. Buy Dec 7, 23
HC Wainwright & Co. Buy Nov 6, 23
Needham Buy Sep 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Tari Leslie CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Aug 14 Buy 0.97 10,000 9,700 294,179 08/14/23
Stein Jeffrey President & CEO President & CEO Aug 08 Buy 0.9577 50,000 47,885 331,602 08/08/23
Stein Jeffrey President & CEO President & CEO Mar 27 Buy 1.0371 50,000 51,855 281,602 03/27/23
Ward Shane COO & CLO COO & CLO Mar 13 Sell 1.53 4,329 6,623 84,576 03/13/23
Tari Leslie CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Mar 13 Sell 1.53 7,562 11,570 190,179 03/13/23
Shah Preetam CFO & CBO CFO & CBO Mar 13 Sell 1.53 6,648 10,171 148,141 03/13/23
Sandison Taylor Chief Medical Office.. Chief Medical Officer Mar 13 Sell 1.53 7,203 11,021 288,550 03/13/23
Sandison Taylor Chief Medical Office.. Chief Medical Officer Sep 12 Sell 0.6849 18,478 12,656 291,753 09/13/22
Tari Leslie CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Sep 12 Sell 0.6849 18,159 12,437 193,741 09/13/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Sep 12 Sell 0.6849 16,199 11,095 221,099 09/13/22
Johnson Brady Vice President, Fina.. Vice President, Finance Mar 21 Sell 0.81 654 530 49,366 03/23/22
Johnson Brady Vice President, Fina.. Vice President, Finance Mar 11 Sell 0.71 945 671 50,020 03/11/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Dec 29 Option 0 9,900 192,431 01/07/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Dec 29 Sell 1.25 5,133 6,416 187,298 01/07/22
Stein Jeffrey President & CEO President & CEO Dec 29 Option 0.00 20,000 489,878 01/07/22
Johnson Brady Vice President, Fina.. Vice President, Finance Dec 29 Option 0 262 51,381 01/07/22
Johnson Brady Vice President, Fina.. Vice President, Finance Dec 29 Sell 1.25 416 520 50,965 01/07/22
Sandison Taylor Chief Medical Office.. Chief Medical Officer Dec 29 Option 0.00 15,600 256,231 01/07/22
Tari Leslie Chief Scientific Off.. Chief Scientific Officer Dec 29 Option 0 2,101 156,652 01/07/22
Tari Leslie Chief Scientific Off.. Chief Scientific Officer Dec 29 Sell 1.25 1,252 1,565 155,400 01/07/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Apr 05 Sell 2.36 3,461 8,168 50,531 04/05/21